Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

March 2, 2015

- Phase 2 data from luspatercept trials in β-thalassemia and MDS patients given as oral presentations at ASH and MDS abstract included in "Best of ASH" session -

- Plans with Celgene to initiate phase 3 clinical trials in both β-thalassemia and MDS in 2015 -

- Sotatercept slowed the progression of vascular calcification in patients with end stage kidney disease -

Acceleron Pharma Announces Executive Appointments and Promotions

Acceleron Pharma Announces Executive Appointments and Promotions

March 6, 2015

- Steven Ertel named Executive Vice President and Chief Operating Officer -

- Matthew Sherman, M.D. named Executive Vice President and Chief Medical Officer -

Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism

Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism

March 2, 2015

Oral presentation at Keystone Symposium for Genomic Instability and DNA Repair Highlights Potential for Use in Sickle Cell Anemia Mutation

Joule Receives Prestigious Frost & Sullivan Technology Innovation Award

Joule Receives Prestigious Frost & Sullivan Technology Innovation Award

March 2, 2015

Bedford, Mass. – Joule, the pioneer of direct, solar recycling of CO2-to-liquid fuels, announced today that its platform was awarded the 2015 Technology Innovation Award by Frost & Sullivan. The award, which recognizes organizations addressing unique and critical challenges, was presented to Joule for its ability to recycle waste carbon dioxide (CO2) into drop-in liquid fuels using sunlight.

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

February 27, 2015

Avedro, Inc., a Boston-based ophthalmic pharmaceutical and medical device company, announced today that on February 24, 2015 the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the Medical Devices Advisory Committee voted in support of approval for Avedro’s new drug application (NDA) for riboflavin ophthalmic solutions with UVA irradiation for use in corneal collagen cross-linking for the treatment of the conditions underlying progressive keratoconus or corneal ectasia following refractive surgery.

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals Reports Year End 2014 Financial Results

February 27, 2015

Conference Call Scheduled Today at 8:30 a.m. ET

Joule Is Poised For Significant Progress in 2015

Joule Is Poised For Significant Progress in 2015

February 23, 2015

Reaches major milestones in 2014 to enable broad industrialization of its carbon-neutral transportation fuels

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

February 17, 2015

Positive early clinical results in three distinct investigational medicines and a strong financial position support advancement of the Agios portfolio into late stage development

Avedro Announces Date for FDA Advisory Committee Meeting

Avedro Announces Date for FDA Advisory Committee Meeting

February 17, 2015

Committee to Review Avedro’s NDA for Riboflavin Ophthalmic Solutions with UVA Irradiation on February 24, 2015

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

February 10, 2015

- Abstract at AACR Translation of the Cancer Genome meeting describes novel approach to discovery of gene control biomarkers -